Author Archives: Taylor Mercado

PMID:  J Allergy Clin Immunol. 2017 05 ;139(5):1710-1713.e2. Epub 2016 Dec 14. PMID: 27986511 Abstract Title:  Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism. Abstract:  [n/a] read more

PMID:  JAMA. 2019 11 5 ;322(17):1722. PMID: 31688874 Abstract Title:  The Relationship Between Herpes Zoster, Syphilis and Chickenpox. Abstract:  [n/a] read more

PMID:  Pediatrics. 2017 Mar ;139(3). Epub 2017 Feb 7. PMID: 28174201 Abstract Title:  Safety of Second-Dose Single-Antigen Varicella Vaccine. Abstract:  BACKGROUND AND OBJECTIVE: In 2006, routine 2-dose varicella vaccination for children was recommended to improve control of varicella. We assessed the safety of second-dose varicella vaccination.METHODS: We identified second-dose single-antigen varicella vaccine reports in the …

Continue reading “This study identified 14,641 adverse events associated with the 2nd dose of the varicella vaccine including anaphylaxis, meningitis, encephalitis, cellulitis, chickenpox, herpes zoster, and deaths.”

PMID:  Vaccine. 2017 04 25 ;35(18):2351-2357. Epub 2017 Mar 27. PMID: 28359621 Abstract Title:  Varicella seroepidemiology in United States air force recruits: A retrospective cohort study comparing immunogenicity of varicella vaccination and natural infection. Abstract:  BACKGROUND/OBJECTIVES: Infection with varicella zoster virus (VZV) produces lifelong immunity, but duration of post-vaccination immunity has not been established. The …

Continue reading “Seroepidemiology indicates that the current varicella zoster virus vaccination is inadequate to maintain herd immunity.”

PMID:  Pediatr Infect Dis J. 2017 06 ;36(6):560-563. PMID: 27997521 Abstract Title:  Laboratory Diagnosis of Breakthrough Varicella in Children. Abstract:  BACKGROUND: Breakthrough varicella (BV) develops in vaccinated persons as a result of infection by wild-type varicella-zoster virus more than 42 days after varicella vaccination. The clinical symptoms are atypical, and clinical diagnosis can be difficult. …

Continue reading “31 of 42 potential breakthrough varicella patients were confirmed to have varicella even after vaccination.”

PMID:  Vaccine. 2017 08 3 ;35(34):4368-4373. Epub 2017 Jul 3. PMID: 28684165 Abstract Title:  Varicella outbreak in a highly-vaccinated school population in Beijing, China during the voluntary two-dose era. Abstract:  BACKGROUND: Two-dose varicella vaccination has been available in Beijing since 2012 in the private sector. We investigated a varicella outbreak in a highly vaccinated elementary …

Continue reading “Children who receive two doses of the varicella vaccine and experience “breakthrough” varicella are contagious.”

PMID:  J Infect Dis. 2018 03 13 ;217(7):1055-1059. PMID: 29409017 Abstract Title:  Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. Abstract:  We studied the relationship between varicella-zoster virus (VZV) DNAemia and development of VZV-specific immunity after administration of live-attenuated zoster vaccine. VZV-DNAemia, detected by polymerase chain reaction (PCR), and VZV-specific effector (Teff) …

Continue reading “Herpes zoster viral DNA is present in vaccinees blood post-vaccination with the Herpes Zoster virus, which could cause Herpes Zoster.”

PMID:  Arch Med Res. 2019 04 ;50(3):111-112. Epub 2019 Aug 5. PMID: 31495387 Abstract Title:  Air Pollution, Multiple Sclerosis and its Relevance to Mexico City. Abstract:  Long-term exposure to air pollution has been linked with the development of neurodegenerative diseases. The proposed mechanisms include neuroinflammation and brain oxidative stress. Multiple sclerosis (MS) is a neurodegenerative …

Continue reading “Air pollution, multiple sclerosis and its relevance to Mexico city.”

PMID:  Vaccine. 2018 08 28 ;36(36):5470-5476. Epub 2017 Aug 1. PMID: 28778616 Abstract Title:  Emerging clinical experience with vaccines against group B meningococcal disease. Abstract:  The prevention of paediatric bacterial meningitis and septicaemia has recently entered a new era with the availability of two vaccines against capsular group B meningococcus (MenB). Both of these vaccines …

Continue reading “More research is needed to truly understand how long meningococcal vaccines remain effective.”

PMID:  PLoS One. 2014 ;9(12):e116024. Epub 2014 Dec 26. PMID: 25541709 Abstract Title:  Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain. Abstract:  The effectiveness of a vaccine is determined not only by the immunogenicity of its components, but especially by how widely it covers the disease-causing …

Continue reading “The 4CMenB vaccine is not only declining in efficacy but has a high incidence of fever associated with its use.”